Introduction {#S0001}
============

Pars plana vitrectomy (PPV) was first introduced by Machemer in 1972. Since then, PPV has undergone a major technical development, becoming a standard procedure for rhegmatogenous retinal detachment (RRD) that produces favorable outcomes.1--[@CIT0003]

Despite all advantages, the formation of cataracts in almost every patient after vitrectomy is an inevitable consequence, with up to 80% of PPV patients developing significant cataracts within the first year.[@CIT0004],[@CIT0005] Most of these patients will then undergo cataract surgery at one point. Often intraocular gas or silicone oil is used as tamponade during PPV. That fact further contributes to cataract formation.[@CIT0006],[@CIT0007]

Advanced instrumentation and modern surgical techniques have led to increasing popularity for combined cataract and vitreoretinal surgery in the last few years, not only in Europe.[@CIT0008]--[@CIT0012] However, despite the increasing acceptance, some vitreoretinal surgeons are still reserved in performing combined procedure in patients with RRD because of concerns regarding higher intra-or postoperative complications rates.[@CIT0013]--[@CIT0015] In addition, in many places, combined procedures are avoided for other reasons including the degree of specialization required to implant premium intraocular lenses as well as general practice patterns.

To our knowledge, this is the first and largest study analyzing the surgical outcome in terms of re-detachment rate after combined phaco-vitrectomy in RRD repair.

Patients and methods {#S0002}
====================

The study was approved by the local ethic committee (Ethikkommission Ostschweiz, BASEC Nr. 2018-00104). All data were anonymized, therefore patient consent was waived by the ethics committee. This research adhered to the tenets of the Declaration of Helsinki.

In this retrospective study, we included all patients who underwent PPV for RRD at the Eye Clinic of Cantonal Hospital Sankt Gallen between January 2013 and December 2017. Patients with other types of retinal detachment, such as tractional or exsudative types, were excluded.

The case notes of these patients were reviewed and following data were included in the statistical analysis: patients characteristics, macula involvement, PVR present at the first visit, lens status, phacoemulsification performed during PPV, type of tamponade (gas or silicone oil), occurrence of re-detachment and reason for re-detachment (proliferative vitreoretinopathy (PVR), insufficiently treated break, new location of RRD).

Surgical technique {#S0002-S2001}
------------------

All surgical procedures were performed under general anesthesia with the Stellaris System (Bausch and Lomb, New York, USA) using three 23 gauge-valved ports. A standard core and peripheral was performed in all patients. Retina reattachment was achieved either by direct fluid-air exchange with drainage of subretinal fluid through main break or by using perfluorocarbon liquid followed by fluid-air exchange. Retinopexy was performed either with transconjunctival cryocoagulation or by endolaser. At the end of surgery, 12% octafluoropropane, 20% sulfur hexafluoride, or silicone oil was applied as intraocular tamponade according to the surgeon's choice.

In phaco-vitrectomy group, three ports were placed at 3.5 mm from the limbus before performing cataract surgery. Phacoemulsification was performed through 2.6 mm clear corneal tunnel incision. Residual cortex was removed using irrigation/aspiration canulas. Subsequently, the anterior chamber was formed with viscoelasticum and vitrectomy was performed as described before. A foldable one-piece hydrophobic acrylic intraocular lens was implanted in the capsular bag using a preloaded injector system before performing fluid-air exchange.

Biometry was obtained using a Carl Zeiss Meditec IOL-Master. In macula off retinal detachment axial length was measured by ultrasound A-scan.

Statistical analysis {#S0002-S2002}
--------------------

The main outcome measure was the rate of retinal re-detachments in patients where a combined phaco-vitrectomy was performed. Subgroup analyses were carried out for patients with primary PVR and/or patients, where silicone oil was used as tamponade to ensure that the outcome is not confounded by these two factors. Furthermore, adjusted calculations were carried out to account for patient characteristics.

The significance between the phacoemulsification and rate of re-detachment was calculated using chi-squared tests with continuity correction, either for all patients or for high-risk subgroups (PVR and silicone oil). Generalized linear models with binomial error distribution were used to test whether outcome depends on PVR or type of tamponade as well as patient characteristics.

A power calculation was performed to demonstrate that the study is adequately powered to detect a meaningful and expected difference in re-detachment rates between the two groups (the number of patients per group needed to show a significant difference with 90% probability was n=342).

All analyses were carried out with R, version 3.3.3.

Results {#S0003}
=======

Overall, 1017 consecutive eyes with retinal detachment were included in this study. The age ranged between 15.2 and 94.5 years with a median age of 63.2 years. Macula was detached in 587 patients (57.7%). In 516 (50.7%) eyes, phacoemulsification was performed simultaneously. Primary PVR was found in 93 (9.3%) patients and silicone oil was used as primary tamponade in 138 (13.6%) patients. Patients' characteristics at baseline are summarized in [Table 1](#T0001){ref-type="table"}.Table 1Patients' characteristicsCharacteristicsn=1017Percentage (%)**Sex** Female35534.9 Male66265.1**Side** Left55254.3 Right46545.7**Macula status** On43042.3 Off58757.7**Lens status** Phakic50149.3 Pseudophakic51650.7**Phacoemulsification**50149.3**Primary PVR**939.1**Tamponade** Gas87986.4 Silicone oil13813.6[^1]

A retinal re-detachment occurred in 103 patients (10.1%). Main reason for re-detachment was an insufficiently treated break which occurred in 53.6% followed by postoperative PVR-reaction in 37.3%. In 9.1%, another break at a different location re-detached the retina again.

No significant difference in the rate of re-detachment was found if phacoemulsification was performed (10.7% (95% CI 8.2--13.7) versus 9.6% (95% CI 7.2--12.6), *p*=0.641).

Significant higher rates of re-detachments were found in patients with a primary PVR (*p*=0.0003) and/or patients where silicone oil was used as primary tamponade (*p*=0.0001). These two factors were clearly associated with each other (X2=290, *p*\<0.0001). Furthermore, patients with a macular involvement had a significant higher re-detachment rate ([Table 2](#T0002){ref-type="table"}). However, if associations between phacoemulsification and retinal re-detachment were calculated individually for the high-risk subgroups, results did not differ from those for all patients ([Table 3](#T0003){ref-type="table"}).Table 2Associations between the occurrence of re-detachment and phacoemulsification, high-risk factors and patients' characteristicsPredictorRe-detachmentChi-squared testNo (n)Yes (n)Yes (%)X^2^*p*-value**Phaco** No4615510.70.220.641 Yes453489.6**PVR** No841839.013.210.0003 Yes732021.5**Tamponade** Gas803768.614.450.0001 Silicone oil1112719.6**Retinopexy** Cryo4355711.62.350.309 Endolaser201188.2 Combined278289.2**Macula status** On397337.74.470.034 Off5177011.9[^2] Table 3Association between the occurrence of re-detachment and phacoemulsification for high-risk groupsRe-detachmentChi-squared testNo (n)Yes (n)Yes (%)X^2^*p*-value**Primary PVR (n=93) Phaco** No471017.50.830.362 Yes261027.8**Primary silicone oil (n=138) Phaco** No661417.50.250.617 Yes451322.4[^3]

Discussion {#S0004}
==========

PPV has brought a lot of advantages for the treatment of retinal detachment. However, in phakic patients, postoperative formation of cataract is an inevitable consequence reported in several studies.[@CIT0004]--[@CIT0006] We therefore began to perform all our vitrectomies combined with phacoemulsification regardless of degree of lens opacity or age threshold. As mentioned before, despite the increasing acceptance within Europe where combined procedures are often performed routinely, some vitreoretinal surgeons are still reserved, in particular in the US, where combined are rarely performed.

In the treatment of RRD in particular, the combined procedure offers a number of advantages. Removing the lens before performing vitrectomy improves visualization of the posterior pole as well as to the peripheral retina, especially if the IOL is implanted at the end of vitrectomy. Good access to the vitreous base without risk of lens touch allows a better shaving of the periphery resulting in a more complete vitrectomy. Furthermore, a combined procedure allows faster visual recovery and avoids the need for phacoemulsification in the vitrectomized eye, which is more complicated.[@CIT0016],[@CIT0017] Intraoperative cataract complications such as posterior capsular rupture with nucleus drop are less of a concern because the vitreoretinal surgeon has the ability to address such issues immediately.

However, a few specific concerns are associated with the combined procedure. Combined procedures may provoke a more intense postoperative inflammation and higher rate of posterior synechiae formation.[@CIT0013]--[@CIT0015] In our experience, we do not have particularly more intense postoperative inflammation. Nevertheless, in some cases, a more aggressive control with additional steroids may reduce these events.[@CIT0009],[@CIT0018] Furthermore, some studies have reported a higher rate of posterior capsule opacification, especially if a gas tamponade was used.[@CIT0013],[@CIT0014],[@CIT0016] Finally, the use of an intraocular tamponade in phaco-vitrectomy may increase the risk of intraocular-lens-related complications, such as intraocular lens decentration, pupillary capture and anterior displacement of the intraocular lens which may induce a myopic shift.[@CIT0019],[@CIT0020] To prevent these complications, in combined surgeries, the IOLs chosen should have an optic diameter of at least 6 mm and should be rigid when unfolded in order to keep the capsular bag stable. In addition, a slightly smaller performed capsulorhexis during cataract surgery and waiving early postoperative dilatation can prevent anterior displacement.

Conclusion {#S0005}
==========

In conclusion, this study refutes the superstition that combined procedures elicit more PVR reaction and therefore increases the risk for re-detachment. This study proves that there is no significant difference in the rate of re-detachment if an additional phacoemulsification was performed.
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[^1]: **Abbreviation:** PVR, proliferative vitreoretinopathy.

[^2]: **Abbreviation:** PVR, proliferative vitreoretinopathy.

[^3]: **Abbreviation:** PVR, proliferative vitreoretinopathy.
